All News

CureDuchenne Webinar with Avidity Biosciences

CureDuchenne Webinar with Avidity Biosciences, a privately held biotech company pioneering a new class of precision medicines based upon antibody-oligonucleotide conjugates, to brief the Duchenne community about Avidity’s research in […]

Avidity Biosciences Receives Investment from CureDuchenne

Investment advances pre-clinical development of novel exon skipping therapies for treatment of patients with Duchenne muscular dystrophy October 17, 2018 08:00 AM Eastern Daylight Time LA JOLLA, Calif.–(BUSINESS WIRE)–Avidity Biosciences, […]